Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)-Reference-Cited by-同舟云学术

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

Published:2020-11-18 Issue:4 Volume:27 Page:975-982
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Sharma Priyanka,Kimler Bruce F.^ORCID,O'Dea Anne,Nye Lauren,Wang Yen Y.,Yoder Rachel,Staley Joshua M.^ORCID,Prochaska Lindsey,Wagner Jamie,Amin Amanda L.^ORCID,Larson Kelsey^ORCID,Balanoff Christa^ORCID,Elia Manana,Crane Gregory,Madhusudhana Sheshadri,Hoffmann Marc,Sheehan Maureen,Rodriguez Roberto,Finke Karissa,Shah Rajvi,Satelli Deepti,Shrestha Anuj,Beck Larry,McKittrick Richard,Pluenneke Robert,Raja Vinay,Beeki Venkatadri,Corum Larry,Heldstab Jaimie,LaFaver Stephanie,Prager Micki,Phadnis Milind,Mudaranthakam Dinesh Pal^ORCID,Jensen Roy A.^ORCID,Godwin Andrew K.^ORCID,Salgado Roberto,Mehta Kathan,Khan Qamar

Funder

University of Kansas Cancer Center

Breast Cancer Research Foundation

National Institute of General Medical Sciences

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is neoadjuvant treatment indicated in triple negative cT1N0 breast cancer?;Revista de Senología y Patología Mamaria;2024-10

2. Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis;World Journal of Clinical Oncology;2024-07-24

3. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations;Cancer;2024-07-10

4. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study;BMC Medicine;2024-06-18

5. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II–III triple negative breast cancer: a retrospective analysis;Journal of Cancer Research and Clinical Oncology;2024-06-05